Jiangsu Hengrui Medicine Co Ltd (600276)
Shanghai Stock Exchange · China · prices in CNY · close of 23 Oct 2026
Key indicators
| Last close | CNY 47.02 |
|---|---|
| 52-week range | 41.89 – 67.85 |
| Return, 1 month / 3 months | +3.2% / −14.4% |
| Return, 1 year / 3 years | −27.8% / +9.2% |
| Trend | Below its 200-day average |
| RSI (14) | 53 |
| Volatility (1 year) | 32.9% |
| Worst drawdown (1 year) | -37.4% |
| Average daily value traded | 3,481.17M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Jiangsu Hengrui Medicine is a pharmaceutical company based in Lianyungang, in Jiangsu province, China. It researches, develops and manufactures prescription medicines, with a focus on cancer treatments, anaesthetics and other hospital-administered drugs. Its customers are mainly hospitals, clinics and healthcare providers in China, and it also supplies medicines to overseas markets. The company produces both generic medicines and its own branded products for doctors and patients.
Jiangsu Hengrui Medicine Co Ltd trades under the code 600276 on the Shanghai Stock Exchange in China, with its price quoted in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Jiangsu Hengrui Medicine Co Ltd (600276) trades on the Shanghai Stock Exchange in China. It last closed at CNY 47.02 on 23 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 698 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 27.8% and over the last three months it fell 14.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 54 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -11.5% | ||
| From 52-week high | -29.8% | ||
| Momentum | 27 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.4% | ||
| 6-month return | -16.6% | ||
| 12-month return, skipping the last month | -30.0% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 32.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.4% | ||
| Liquidity | 99 · Strong | Trades actively. | |
| Average daily value traded | 3,481.17M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +0.8% |
|---|---|
| 1 month | +3.2% |
| 3 months | −14.4% |
| 6 months | −16.6% |
| 1 year | −27.8% |
| 3 years | +9.2% |
| 5 years | −7.6% |
Signals
| 50-day / 200-day average | 47.22 / 53.15 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.38 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 Jun 2023 | CNY 0.1600 |
| 5 Jul 2022 | CNY 0.1600 |
| 10 Jun 2021 | CNY 0.2400 |
| 25 May 2020 | CNY 0.2760 |
| 28 Mar 2019 | CNY 0.2640 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.